CNS Pharmaceuticals (NASDAQ:CNSP) Stock Price Up 0.4% – Still a Buy?

CNS Pharmaceuticals, Inc. (NASDAQ:CNSP) shares were up 0.4% on Wednesday . The stock traded as high as $4.71 and last traded at $4.61. Approximately 30,763 shares were traded during trading, a decline of 63% from the average daily volume of 82,085 shares. The stock had previously closed at $4.59.

Wall Street Analyst Weigh In

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of CNS Pharmaceuticals in a research report on Monday, April 20th. One equities research analyst has rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, CNS Pharmaceuticals has a consensus rating of “Hold” and a consensus target price of $20.00.

CNS Pharmaceuticals Trading Up 0.4%

The business’s 50 day moving average is $4.05 and its two-hundred day moving average is $4.66. The company has a market cap of $6.73 million, a PE ratio of -0.16 and a beta of 3.06.

CNS Pharmaceuticals (NASDAQ:CNSP) last announced its quarterly earnings results on Thursday, May 14th. The company reported ($7.30) EPS for the quarter, topping the consensus estimate of ($8.82) by $1.52.

Insider Buying and Selling

In related news, Director Faith L. Charles acquired 7,100 shares of the stock in a transaction on Monday, May 18th. The stock was bought at an average cost of $4.79 per share, with a total value of $34,009.00. Following the transaction, the director directly owned 7,100 shares in the company, valued at approximately $34,009. This represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this link. Insiders own 0.01% of the company’s stock.

Institutional Investors Weigh In On CNS Pharmaceuticals

Hedge funds have recently modified their holdings of the business. Armistice Capital LLC purchased a new stake in shares of CNS Pharmaceuticals in the 2nd quarter worth approximately $335,000. Ikarian Capital LLC purchased a new stake in CNS Pharmaceuticals during the fourth quarter valued at approximately $241,000. Finally, Boothbay Fund Management LLC purchased a new stake in CNS Pharmaceuticals during the fourth quarter valued at approximately $71,000. Hedge funds and other institutional investors own 14.02% of the company’s stock.

About CNS Pharmaceuticals

CNS Pharmaceuticals, Inc, headquartered in Houston, Texas, is a clinical-stage biopharmaceutical company focused on developing therapies for aggressive central nervous system tumors. The company’s lead candidate, berubicin, is an anthracycline derivative engineered to cross the blood-brain barrier for the treatment of glioblastoma multiforme and other brain cancers. In addition to berubicin, CNS Pharmaceuticals is advancing WP1066, an immunotherapy agent designed to inhibit the STAT3 signaling pathway and enhance anti-tumor immune activity in the tumor microenvironment.

Berubicin has completed a Phase 1 clinical trial in patients with recurrent glioblastoma, where it demonstrated proof-of-concept signals, and is currently in Phase 2 development.